http://www.rxpgnews.com/ Medical News and Information Thu, 21 Aug 2008 02:00:28 PST en-us http://www.rxpgnews.com/pagetsdisease/Single_Infusion_of_Zoledronic_Acid_More_Effective__2305_2305.shtml Pagets Disease A head-to-head study published in The New England Journal of Medicine reports that a single infusion of the investigational bisphosphonate, zoledronic acid 5 mg solution, offers superior efficacy, longer period of remission, and faster onset of action compared to the oral bisphosphonate risedronate (Actonel®) in patients with Paget’s disease. Thu, 08 Sep 2005 01:08:00 PST http://www.rxpgnews.com/pagetsdisease/Single_Infusion_of_Zoledronic_Acid_More_Effective__2305_2305.shtml http://www.rxpgnews.com/pagetsdisease/Studies_confirm_new_treatments_for_Paget_s_disease_2251_2251.shtml Pagets Disease Two studies led by researchers at The University of Auckland's Faculty of Medical and Health Sciences have pioneered new, more effective treatment for two forms of Paget's disease - a chronic and often painful bone disease. Mon, 05 Sep 2005 23:56:00 PST http://www.rxpgnews.com/pagetsdisease/Studies_confirm_new_treatments_for_Paget_s_disease_2251_2251.shtml http://www.rxpgnews.com/pagetsdisease/European_Commission_Approves_Zoledronic_acid_for_t_1215_1215.shtml Pagets Disease Novartis Pharma AG announced today that Aclasta® (zoledronic acid 5mg solution for infusion) has been granted Marketing Authorization by the European Commission for the treatment of Paget's disease of the bone in all 25 European member states, as well as Norway and Iceland. This represents the first approval for Aclasta. Sun, 24 Apr 2005 08:13:00 PST http://www.rxpgnews.com/pagetsdisease/European_Commission_Approves_Zoledronic_acid_for_t_1215_1215.shtml